KOD News and Press, Kodiak Sciences Inc From 03/15/21

Kodiak Sciences is expected to have three trial readouts in 2022 with use of its drug KSI-301. If all studies end up being successful, then 3 BLA filings would happen. The first most important trial readout would be from the phase 2b/3 DAZZLE study using KSI-301 to treat patients with...

Kodiak Sciences (KOD): Q4 GAAP EPS of -$0.97 misses by $0.24. Cash, cash equivalents and marketable securities of $969M.Press Release For further details see: Kodiak Sciences EPS misses by $0.24

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researchin...

Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting ...

Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition PR Newswire PALO ALTO, Calif. , Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a bio...

BMO analyst Matthew Lucchini has downgraded shares of Kodiak Sciences (KOD) from outperform to market perform due to "limited near-term upside" of anti-VEGF therapy candidate KSI-301.New price target is $143, a significant drop from its mid-afternoon share price of $155.80."We are stepping as...

Dextenza sales continue to grow despite the fact that COVID-19 cases are still continuing to rise. Recently, OCUL signed a deal to commercialize Dextenza and OTX-TIC internationally, proving the value of the platform. OCUL recently reported strong results for both its Dextenza and...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. 2020 was a year of monumental progress in renewable energ...

The following slide deck was published by Kodiak Sciences Inc. in conjunction with this event. For further details see: Kodiak Sciences (KOD) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow